Chart: Iressa FDA Reviewers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Iressa FDA Reviewers
You may also be interested in...
Iressa Reviewers
FDA staff who participated in the review of AstraZeneca’s EGFR tyrosine kinase inhibitor gefitinib; a feature of the Pink Sheet’s Drug Review Profile series.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product